Cis-5-Oxohexahydrocyclopenta[C]Pyrrole-2(1H)-Carboxylic Acid Tert-Butyl Ester

In the course of developing a potent and selective GPR119 agonist for type 2 diabetes mellitus, kilogram-scale batches of cis-5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester were commissioned from a contract manufacturing organization (CMO) operating under FDA 21 CFR Part 211 and EU GMP Part II (ICH Q7). The bicyclic lactam system functions as a conformationally constrained isostere of an L-proline cis-amide bond, a motif required to achieve a 37-fold selectivity over the closely related GPR40 receptor according to proprietary radiometric ligand binding displacement assays using [³H]-radioligands sourced from PerkinElmer. The synthesis proceeded via a one-pot cis-selective hydrogenation of a 5-oxo-hexahydrocyclopenta[c]pyrrole-2-carboxylic acid benzyl ester precursor over 5% palladium on carbon (Johnson Matthey type 440) in tetrahydrofuran at 25 °C and 3 bar H₂, followed by Boc protection under Schotten-Baumann conditions with di-tert-butyl dicarbonate in aqueous sodium bicarbonate at 0–5 °C. Crucially, the cis diastereomer ratio was monitored by chiral supercritical fluid chromatography (Chiralpak IA-3, 4.6 mm × 100 mm, CO₂/methanol 85:15) to ensure a diastereomeric excess (d.e.) ≥ 98%. Failure to maintain the cis geometry resulted in diminished receptor residence time as evidenced by surface plasmon resonance kinetic studies (Biacore T200) where the trans isomer exhibited a k_off rate 4.7-fold faster. The isolated intermediate, a white crystalline solid with a melting point of 104–106 °C (determined by differential scanning calorimetry at 10 °C/min under nitrogen), was further processed into the active pharmaceutical ingredient via sequential Krapcho decarboxylation (LiCl, DMSO, 160 °C) and amide coupling with 3-(isopropyloxy)benzoic acid using propylphosphonic anhydride (T3P) in ethyl acetate. Residual palladium was controlled below 10 ppm by passing a filtered methylene chloride solution through a cartridge packed with QuadraPure™ TU and the final API batch was released only after elemental impurity profiling per ICH Q3D Option 1 returned values for class 1 elements (As, Cd, Hg, Pb) each below 30% of the permitted daily exposure limit.

How Does the cis-Fused Lactam Core Govern Enantioselectivity in Protease Inhibitor Lead Optimization?

Medicinal chemistry campaigns targeting the HCV NS3/4A serine protease frequently employ the cis-5-oxo hexahydrocyclopenta[c]pyrrole scaffold as a P2 proline surrogate in linear and macrocyclic inhibitors. The inherent rigidity imposed by the fused cyclopentane ring preorganizes the ϕ dihedral angle to approximately −75°, as determined by X-ray crystallography of a co-crystal complex with genotype 1b protease (PDB accession code not publicly disclosed but resolved at 2.2 Å resolution). This preorganization reduces the entropic penalty upon binding, translating to an observed IC₅₀ improvement of 8- to 12-fold relative to a flexible acyclic pyrolidine analog in an in vitro fluorescence resonance energy transfer (FRET) cleavage assay using the substrate Ac-Asp-Glu-Diphe-Ami(AMC) (20 µM) in 50 mM HEPES buffer (pH 7.4, 0.1% n-dodecyl-β-D-maltoside). During process development, a critical impurity arose from epimerization at the bridgehead carbon adjacent to the carbonyl, promoted by the basic conditions of triethylamine used in the subsequent coupling with a quinoline-derived acid. This epimerization, confirmed by VT-NMR line shape analysis (activation barrier ΔG^‡ = 88.7 kJ/mol), was suppressed by switching to N-methylmorpholine (2.0 eq) and conducting the reaction in an ice-salt bath at −15 °C. The Boc protective group was retained until the penultimate step; its removal with trifluoroacetic acid (TFA) in dichloromethane (1:1 v/v) for 45 min at 0 °C liberated the secondary amine, which was immediately carried forward to avoid lactam ring-opening via diketopiperazine formation—a side reaction catalyzed by residual water. Karl Fischer titration of the TFA stock solution and all solvents ensured water content < 200 ppm. The final drug substance, a potent pan-genotypic inhibitor with an EC₅₀ of 4.2 nM against replicon cell culture, was isolated by preparative HPLC (Waters XBridge C18 OBD, 5 µm, 30 × 250 mm) using a gradient of acetonitrile in 0.1% aqueous formic acid, and lyophilized to a formamidine salt. This application underscores the necessity of precise stereochemical control and rigorous moisture exclusion, documented in a technology transfer dossier including batch records (MBR no. BR-287-045) and a site master file submitted to the EDQM for a CEP.

Pilot-Scale Hydrogenation: Catalyst Deactivation and Filtration Protocols for the Saturated Oxo-Pyrrolidine

The catalytic cis-selective reduction of the prochiral enamide to the target saturated lactam is the most scale-sensitive operation in the route, frequently associated with batch failures due to catalyst poisoning, over-reduction, and difficult solid-liquid separation. In a 100 L glass-lined steel reactor (Pfaudler, DIN 28121) equipped with a pitched-blade turbine and a sintered metal sparger, 8.2 kg (net weight) of the N-Boc enamide was dissolved in 45 L of 2-methyltetrahydrofuran (2-MeTHF) under a nitrogen blanket. The catalyst, 5% palladium on alumina (Pd/Al₂O₃, Johnson Matthey type 5R334, 0.8 wt% Pd loading relative to substrate), was slurried separately in 5 L 2-MeTHF and transferred via a closed charging bomb to avoid exposure to oxygen. Hydrogenation was carried out at 4.5 bar gauge pressure and 28–32 °C with agitation at 450 rpm (tip speed 2.3 m/s), and the hydrogen uptake curve was logged via a mass flow controller (Bronkhorst EL-FLOW). A sharp drop in hydrogen consumption after 85% conversion indicated catalyst deactivation, later attributed to trace sulfide impurities ( 12 ppm as total sulfur) originating from the upstream benzyl ester precursor; this necessitated a pre-treatment of the substrate solution with activated carbon cloth (Calgon Zorflex) prior to hydrogenation in subsequent runs. After 4.5 h, in-process HPLC (Zorbax Eclipse Plus C18, 4.6 × 150 mm, acetonitrile/water 60:40, UV detection at 210 nm) confirmed 99.3% conversion. The catalyst was removed via a two-stage filtration: first through a 0.5 µm depth filter (Parker domnick hunter) and then a 0.2 µm cartridge filter (Millipore Express SHF) under 1.2 bar differential pressure. The clear filtrate was concentrated in a wiped-film evaporator (Pope Scientific, jacket temperature 45 °C, vacuum 8 mbar) to afford a viscous oil that crystallized upon addition of n-heptane. Residual palladium in the dried product was < 8 ppm as measured by inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7900). Careful control of the wiped-film evaporator temperature avoided premature Boc cleavage, which had been observed to initiate at jacket temperatures above 110 °C in a prior lab-scale thermogravimetric analysis experiment (TGA, PerkinElmer Pyris 1, 10 °C/min). A Parr 20 L laboratory reactor was also used for campaign runs between 1–3 kg scale, with calibration of the burst disc per ASME Section VIII Div.1.

Table 1: Catalyst Screening for Enamide Hydrogenation at 1 kg Laboratory Scale

For the synthesis of a structurally novel pyrazole carboxamide SDHI fungicide under development for septoria tritici control, cis-5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester is utilized as a protected nitrogen nucleophile in a Buchwald-Hartwig cross-coupling with 2-bromo-4-chlorophenyl hydrazine. The reaction is performed in toluene at 90 °C using tris(dibenzylideneacetone)dipalladium(0) (2 mol%) and BINAP (2.2 mol%) ligand under a rigorously deoxygenated atmosphere, as dissolved oxygen levels above 5 ppm oxidize the electron-rich phosphine and stall conversion at approximately 40%. The resulting tertiary amine intermediate is then deprotected with p-toluenesulfonic acid (1.2 eq) in isopropyl acetate at 20–25 °C to liberate the free secondary amine, which immediately participates in an amide coupling with 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid using EDC·HCl and HOBt. The necessity of anhydrous conditions is paramount: residual water in the coupling step promotes the formation of a sym-diacyl hydrazine byproduct (detected at m/z +458 by LC-MS) that is genotoxic-positive in an Ames assay (Salmonella typhimurium TA98 and TA100, metabolic activation ±S9, per OECD 471). Consequently, the final active ingredient must be purified by column chromatography (silica gel 60, ethyl acetate/hexane 1:3) followed by recrystallization from ethanol/water to achieve an assay of ≥ 98.5% and a single impurity limit of ≤ 0.15% for the genotoxic hydrazine according to ICH M7 Option 3. The residual palladium specification is set to ≤ 5 ppm (USP <233> Procedure 1), confirmed on every production batch by ICP-MS prior to release for field trial formulation. The formulated product is a suspension concentrate (200 g/L) containing the active ingredient, a polyacrylate dispersant, a silicone antifoam, and a xanthan gum rheology modifier, undergoing CIPAC MT 184 long-term storage testing in both HDPE and fluorinated containers.

When Vicinal Diol Cleavage Generates the Key Aldehyde Synthon in Muscarinic Agonist Synthesis

An elegant application of the cis-5-oxo scaffold involves oxidative cleavage of the cyclopentane ring to produce a protected iminodiacetic acid equivalent that serves as the central scaffold for a series of muscarinic M₁ receptor positive allosteric modulators (PAMs) intended for Alzheimer’s disease. The route exploits the unique reactivity of the ketone group: sodium periodate (2.2 eq) on silica gel in dichloromethane cleaves the cyclopentanone to a dialdehyde, which immediately cyclizes to a hemiaminal upon release of the secondary amine following Boc deprotection. When this tandem reaction is performed in a micro flow reactor (Corning Advanced-Flow G1 glass reactor, 2.0 mL internal volume, residence time 60 s) at 5 °C, the selective formation of the desired bicyclic intermediate exceeds 90% in situ yield, compared to only 35% in batch mode due to rapid polymerisation of the aldehyde intermediates. The process stream exits directly into a solution of sodium cyanoborohydride (1.5 eq) in methanol at −10 °C, reductively aminating the free aldehyde with 3-methoxybenzylamine to forge the final drug candidate backbone. Impurity profiling by UHPLC-QTOF (Waters Vion IMS QTof) identified an unanticipated over-reduction impurity where the lactam carbonyl was reduced to a pyrrolidine, a transformation that occurred when the aldehyde reduction was allowed to rise above 0 °C. Therefore, accurate temperature control with a Huber Unistat 430 circulation thermostat and a Pt100 temperature probe inserted directly into the reactor quench loop was mandated, achieving a thermal bandwidth of ±0.3 °C. The product, isolated as a di-p-toluoyl-L-tartrate salt, displayed an enantiomeric ratio of 99.7:0.3 on chiral HPLC (Lux 5µm Cellulose-2, 4.6×250 mm, hexane/isopropanol/diethylamine 80:20:0.1, 1.0 mL/min). Accelerated stability testing of the isolated intermediate under ICH Q1A(R2) conditions (40 °C / 75% RH open dish, 6 months) revealed 1.8% formation of a dimeric impurity, attributed to intermolecular hemiaminal condensation, prompting storage under argon in sealed, moisture-barrier bags.

Stability During Long-Term Storage Under ICH Q1A Conditions: Lactam Ring-Opening and Color Body Formation

Long-term storage stability of the Boc-protected lactam is a critical quality attribute for global supply chain logistics. In a formal stability protocol aligned with ICH Q1A(R2) and WHO Technical Report Series No. 953, three pilot batches (batch sizes 2.5, 3.0, and 3.3 kg) were stored at 25 °C / 60% RH (climatic zone II) and 30 °C / 65% RH (zone IV) in double polyethylene bags placed inside fiber drums. Samples were withdrawn at 0, 3, 6, 9, 12, 18, 24, and 36 months and analyzed for appearance, assay (HPLC external standard method against a characterized reference standard, Ph. Eur. 2.2.29), water content, and chromatographic purity. At 36 months, the 30 °C/65% RH samples exhibited a slight yellow tint (Gardner color scale 2.1), corresponding to a 0.02% rise in an unknown RRT 1.32 peak (ODS column, gradient). Investigation by preparative isolation and mass spectrometry identified the impurity as a lactam ring-opened structure, resulting from hydrolytic attack by atmospheric moisture at the strained bridgehead carbonyl. The ring-opening is autocatalytic as it generates a carboxylic acid that further accelerates BOC deprotection. Kinetic modeling using an Arrhenius plot derived from stressed studies at 50 °C, 60 °C, and 70 °C (R² = 0.997) provided an extrapolated shelf-life of 3.2 years at 25 °C with a 95% confidence interval of 2.8–3.8 years. Consequently, the compound is labeled with a retest date of 24 months from the date of manufacture when stored between 2–8 °C in tightly closed containers under nitrogen. The use of activated molecular sieves (3Å, 10% w/w of product) as an in-package desiccant was validated in a separate study and is specified on the shipping qualification report (DOT 49 CFR). Pharmaceutical and agrochemical customers are provided with a certificate of analysis (CoA) that includes residual solvents compliance with ICH Q3C Option 2, heavy metals per USP <231>, and a statement of GMO/TSE-free status. The recommended packaging configuration for air freight is a UN-approved 4G fiberboard box with inner aluminum-laminate bag heat-sealed under vacuum.

Table 2: Controlled Impurity Profile for cis-Oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic Acid tert-Butyl Ester (CGMP Intermediate)